Current status of the conjugate vaccine against Streptococcus Pneumoniae
DOI:
https://doi.org/10.51481/amc.v48i2.243Keywords:
S. pneumoniae, vaccine, serotypeAbstract
The heptavalent S. pneumoniaeconjugate vaccine hasshown to be safe and effective in preventing pediatric inva-sive infections and otitis media caused by S. pneumoniae.The routine use of these vaccines has dramatically reducedthe incidence of invasive pneumococcal diseases in childrenyounger than 2 years old and because of a reduction incolonization of the children's nasopharynx, the transmis-sion from child to adult has been reduced and the number of secondary S. pneumoniaeinfections in adults. Anotherbenefit of the routine use of this vaccine has been the reduc-tion of vaccine-type antimicrobial resistant strains. Basedon the S. pneumoniaeserotype distribution in Costa Rica,the predicted vaccine protection is calculated in 74%.
Downloads
References
Preventing pneumococcal disease among infants and young children:recommendations of the Advisory Committee on ImmunizationPractices (ACIP) MMWR 2000; 49:1-38.
MMWR CDC Prevention of pneumococcal disease: recommenda-tions of the Advisory Committee on Immunization Practices (ACIP).1997; 46:1-24.
Peter G, Klein JO. Streptococcus pneumoniae. En: Long SS,Pickering LK, Prober CG, eds. Principles and practice of pediatricinfectious diseases. 2nd ed. Philadelphia: Churchill Livingstone.2003:739-46.
World Health Organization. Pneumococcal vaccine.Wkly EpidemiolReport 2003; 14:110-9
.5.Dagan R, Relamed M, Piglansky L, Greenberg D, Abramson O,Mendelman PM, et al. Reduction of nasopharyngeal carriage of pneu-mococci during the second year of life by a heptavalent conjugatepneumococcal vaccine. J Infect Dis. 1996; 174:1271-78.
Shinefield HR, Black SB. Postlicensure surveillance forHaemophilus influenzae type b invasive disease alter use ofHaemophilus influenzae type b oligosaccharide CRM197 conjugatevaccine in the large defined United Status population: a four yeareight month follow up. Pediatr Infect Dis J. 1995; 14:978-981.
CDC. Progress toward elimination of Haemophilus influenzae type bamong infants and children: United States, 1987-1993. MMWR1994; 43:144-8.
Centers for Disease Control and Prevention. Prevention of pneumo-coccal disease: recommendation of the Advisory Committee onImmunization Practices (ACIP), MMWR. 1997; 46:1-24.
Ulloa R, Avila M, Herrera M, Herrera J, Arguedas A. Invasive pneu-mococcal disease in Costa Rican children: a seven year survey.Pediatr Infect Dis J. 2003; 22:1069-74.
Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al.Efficacy of a Pneumococcal conjugate vaccine against acute otitismedia. N Engl J Med. 2001; 344:403-409.
Niemelá M, Uhari M, Möttönen M, Pokka T. Cost arising from otitismedia. Acta Paediatr. 1999; 88:553-556.
Gates GA. Cost-effectiveness considerations in otitis media treat-ment. Otolaryngol Head Neck Surg. 1996; 14:525-530.
Kaplan B, Wandstrat TL, Cunningham JR. Overall cost in the treat-ment of otitis media. Pediatr Infect Dis J. 1997; 16:S9-S11.
Bondy J, Berman S, Glazner J, Lezotte D. Direct expenditures relat-ed to otitis media diagnosis: extrapolations from a pediatric Medicaidcohort. Pediatrics. 2000; 105:1323-1323.
National Committee for Clinical and Laboratory Standards: twelfthinformational supplement. NCCLS document. M100-S12 (ISBN 1-56238-454-6). NCCLS, 940 West Valley Road, Suite 1400, Wayne,Pennsylvania 12807-1898, USA 2002.
Hava DL, Le Mieux J. From nose to lung: the regulation behindStreptococcus pneumoniae virulence factors. Molec Microbiol. 2003;50:1103-10.
Ghaffar F, Friedland I, Mccraken G. Dynamics of nasopharyngealcolonization by S.pneumoniae. Pediatr Infect Dis J. 1999;
: 638-46.70
Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson K,Spratt B. Temporal and geographic stability of the serogroup- specif-ic invasive disease potential of Streptococcus pneumoniae in chil-dren. J Infect Dis. 2004; 190:1203-11.
Fernebro J, Andersson I, Sublett J, Morfeldt E, Novak R, TuomanenE, et al. Capsular expression in Streptococcus pneumoniae negative-ly affects spontaneous and antibiotic-induced lysis and contributes toantibiotic tolerance. J Infect Dis. 2004; 189:328-38. Epub 2003 Dec30.
American Academy of Pediatrics. Pneumococcal Infections En:Pickering LK, ed. Red book: 2003 Report of the Committee onInfectious Diseases. 26th ed. Elk Grove Village, IL: AmericanAcademy of Pediatrics; 2003:496-500.
Arguedas A, Dagan R, Guevara S, Porat N, Soley C, Pérez A, BrillaR. Middle ear fluid Streptococcus pneumoniae serotype distributionin Costa Rican children with otitis media. Pediatr Infect Dis J. 2005;24:631-634.
Arguedas A, Dagan R, Soley C, Loaiza C, Knudsen K, Porat N, PerezA, Brilla E, Herrera ML. Microbiology of otitis media in Costa Ricanchildren, 1999 through 2001. Pediatr Infect Dis J. 2003; 22:1063-8.
Dagan R. Vacunas neumocóccicas conjugadas para prevenir laportación y propagación de neumococos resistentes a los antibióticos.Arch. argent pediatr. 2002:100:19-24.
Vives M, García ME, Saenz P, Mora M, Mata L, Sabharwal H, et al.Nasopharyngeal colonization in Costa Rican children during the firstyear of life. Pediatr Infect Dis J. 1997; 16:852-58.
García JA, Fresnadillo MJ. Dynamics of nasopharyngeal colonizationby potential respiratory pathogens. J Antimicrob Chemother. 2002;50:59-73.
Fattom A, Lue C, Szu SC, Mestecky J, et al. Serum antibody responsein adult volunteers elicited by injection of Streptococcus pneumoniaetype 12F polysaccharide alone or conjugated to diphtheria toxoid.Infect Immun. 1990; 58:2309-12. 27.Nieminen T, Kayhty H, Leroy O, Eskola J. Pneumococcal conju-gate vaccination in toddlers: mucosal antibody response measured ascirculating antibody-secreting cells and as salivary antibodies.Pediatr Infect Dis J. 1999; 18:764-72. 28.Adderson EE. Antibody repertoires in infants and adults: effects ofT-independent and T-dependent immunizations. Springer SeminImmunopathol. 2001; 23:387-403.
Perez-Melgosa M, Ochs HD, Linsley PS, Laman JD, van Meurs M,Flavell R, et al. Carrier-mediated enhancement of cognate T cell help:the basis for enhanced immunogenicity of meningococcal outermembrane protein polysaccharide conjugate vaccine. Eur J Immunol.2001; 31:2373-81.
Wasserman RL, Sorensen R. Evaluating children with respiratorytract infections: the role of immunization with bacterial polysaccha-ride vaccine. Pediatr Infect Dis J. 1999; 18:157-163.
Huo Z, Spencer O, Miles J, Johnson J, Holliman R, Sheldon J, et al.Antibody response to pneumolysin and to pneumococcal capsularpolysaccharide in healthy individuals and Streptococcus pneumoniaeinfected patients. Vaccine. 2004; 22:1157-61.
Obaro SK, Adegbola RA, Chang I, Banya WA, Jaffar S, Mcadam K,et al. Safety and immunogenicity of a nonavalent pneumococcal vac-cine conjugated to CRM 197 administered simultaneously but in aseparate syringe with diphtheria, tetanus and pertussis vaccines inGambian infants. Pediatr Infect Dis J. 2000; 19: 463-469.
Dagan R, Kaythty H, Wuorimaa T, Yaich M, Bailleux F, Zamir O, etal. Tolerability and immunogenicity of an eleven valent mixed carri-er Streptococcus pneumoniae capsular polysaccharide-diphtheria tox-oid or tetanus protein conjugate vaccine in Finnish and Israeli infants.Pediatr Infect Dis J. 2004; 23:91-98.
Whitney C, Farley M, Hadler J, Harrison L, Bennett NM, Lynfield R,et al. Decline in invasive pneumococcal disease after the introductionof protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.
Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen J, et al.Efficacy, safety and immunogenicity of heptavalent pneumococcalconjugate vaccine in children. Pediatr Infect Dis J. 2000; 19: 187-195.
Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, etal. Postlicensure surveillance for pneumococcal invasive disease afteruse of heptavalent pneumococcal conjugate vaccine in NorthernCalifornia Kaiser Permanente. Pediatr Infect Dis J. 2004; 23: 485-489.
Palmu AI, Verho J, Jokinen J, Karma P, Kilpi T. The seven valentpneumococcal conjugate vaccine reduces tympanostomy tube place-mente in children. Pediatr Infect Dis J. 2004; 23:732-738.
Hausdorff W, Yothers G, Dagan R, Kilpi T, Pelton S, Cohen R, et al.Multinacional study of pneumococcal serotypes causing acute otitismedia in children. Pediatr Infect Dis J. 2002; 21:1008-16.
Dagan R, Givon-Lavi N, Shkolnik L, Yagupsky P, Fraser D. Acuteotitis media caused by antibiotic-resistant Streptococcus pneumoniaein southern Israel: implication for immunizing with conjugate vac-cines. J Infect Dis. 2000; 181:1322-9.
Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impactof the pneumococcal conjugate vaccine on otitis media. Pediatr InfectDis J. 2003; 22:10-6.
Arguedas A, Loaiza C, Pérez A, Vargas F, Herrera M, Rodríguez G, etal. Microbiology of otitis media in Costa Rican children. PediatrInfect Dis J. 1998; 17:680-9.
Porat N, Arguedas A, Spratt B, Trefler R, Brilla E, Loaiza C, et al.Emergence of penicillin nonsusceptible Streptococcus pneumoniaeclones of non-vaccine serotypes: Serotype 11A and 15B/C variants ofresistant clones of serotypes included in the pneumococcal conjugatevaccines. J Infect Dis. 2004; 190:2154-2161.
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
